Anhui Fengyuan Pharmaceutical Co Ltd - Asset Resilience Ratio
Anhui Fengyuan Pharmaceutical Co Ltd (000153) has an Asset Resilience Ratio of 1.81% as of December 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Anhui Fengyuan Pharmaceutical Co Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2020)
This chart shows how Anhui Fengyuan Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See 000153 net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Anhui Fengyuan Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 000153 stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥80.69 Million | 1.81% |
| Total Liquid Assets | CN¥80.69 Million | 1.81% |
Asset Resilience Insights
- Limited Liquidity: Anhui Fengyuan Pharmaceutical Co Ltd maintains only 1.81% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Anhui Fengyuan Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Anhui Fengyuan Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC |
Drug Manufacturers - Specialty & Generic | 43.05% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 1.96% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Guobang Pharma Ltd
SHG:605507 |
Drug Manufacturers - Specialty & Generic | 8.47% |
Annual Asset Resilience Ratio for Anhui Fengyuan Pharmaceutical Co Ltd (2016–2020)
The table below shows the annual Asset Resilience Ratio data for Anhui Fengyuan Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-12-31 | 0.19% | CN¥6.99 Million ≈ $1.02 Million |
CN¥3.64 Billion ≈ $532.09 Million |
-0.09pp |
| 2019-12-31 | 0.28% | CN¥9.87 Million ≈ $1.44 Million |
CN¥3.56 Billion ≈ $520.88 Million |
+0.02pp |
| 2018-12-31 | 0.26% | CN¥7.79 Million ≈ $1.14 Million |
CN¥3.01 Billion ≈ $440.16 Million |
-0.23pp |
| 2017-12-31 | 0.49% | CN¥13.47 Million ≈ $1.97 Million |
CN¥2.77 Billion ≈ $405.00 Million |
-0.32pp |
| 2016-12-31 | 0.81% | CN¥20.06 Million ≈ $2.94 Million |
CN¥2.49 Billion ≈ $364.42 Million |
-- |
About Anhui Fengyuan Pharmaceutical Co Ltd
Anhui Fengyuan Pharmaceutical Co., Ltd. researches and develops, produces, and sells medicines in China. The company also exports its products. Anhui Fengyuan Pharmaceutical Co., Ltd. was incorporated in 1997 and is based in Hefei, China.